Entrada Therapeutics (NASDAQ:TRDA) Given Buy Rating at HC Wainwright

Entrada Therapeutics (NASDAQ:TRDA)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 81.49% from the stock’s previous close.

Several other equities analysts have also issued reports on TRDA. Roth Mkm set a $13.00 target price on Entrada Therapeutics in a research report on Thursday, November 6th. Guggenheim raised shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Oppenheimer assumed coverage on shares of Entrada Therapeutics in a report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.50.

Entrada Therapeutics Stock Up 1.3%

TRDA stock opened at $11.02 on Wednesday. Entrada Therapeutics has a twelve month low of $4.93 and a twelve month high of $13.82. The company has a market cap of $421.18 million, a P/E ratio of -4.43 and a beta of -0.12. The business’s fifty day moving average is $10.80 and its 200-day moving average is $8.15.

Insider Activity

In other news, CFO Kory James Wentworth sold 8,910 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $9.98, for a total transaction of $88,921.80. Following the completion of the transaction, the chief financial officer directly owned 110,026 shares of the company’s stock, valued at $1,098,059.48. This represents a 7.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.59% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Entrada Therapeutics

Several institutional investors have recently bought and sold shares of TRDA. Russell Investments Group Ltd. grew its stake in shares of Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after acquiring an additional 3,707 shares in the last quarter. State of Wyoming grew its position in Entrada Therapeutics by 130.9% in the second quarter. State of Wyoming now owns 7,575 shares of the company’s stock valued at $51,000 after purchasing an additional 4,295 shares in the last quarter. AXQ Capital LP acquired a new stake in Entrada Therapeutics in the 3rd quarter valued at $67,000. Occudo Quantitative Strategies LP acquired a new stake in Entrada Therapeutics in the 2nd quarter valued at $68,000. Finally, Inscription Capital LLC bought a new stake in Entrada Therapeutics during the 3rd quarter worth about $69,000. Institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.